Literature DB >> 24647492

A novel, automated nutrition screening system as a predictor of nutritional risk in an oncology day treatment unit (ODTU).

J Abbott1, L Teleni, D McKavanagh, J Watson, A McCarthy, E Isenring.   

Abstract

PURPOSE: Paper-based nutrition screening tools can be challenging to implement in the ambulatory oncology setting. The aim of this study was to determine the validity of the Malnutrition Screening Tool (MST) and a novel, automated nutrition screening system compared to a 'gold standard' full nutrition assessment using the Patient-Generated Subjective Global Assessment (PG-SGA).
METHODS: An observational, cross-sectional study was conducted in an outpatient oncology day treatment unit (ODTU) within an Australian tertiary health service. Eligibility criteria were as follows: ≥ 18 years, receiving outpatient anticancer treatment and English literate. Patients self-administered the MST. A dietitian assessed nutritional status using the PG-SGA, blinded to the MST score. Automated screening system data were extracted from an electronic oncology prescribing system. This system used weight loss over 3 to 6 weeks prior to the most recent weight record or age-categorised body mass index (BMI) to identify nutritional risk. Sensitivity and specificity against PG-SGA (malnutrition) were calculated using contingency tables and receiver operating curves.
RESULTS: There were a total of 300 oncology outpatients (51.7% male, 58.6 ± 13.3 years). The area under the curve (AUC) for weight loss alone was 0.69 with a cut-off value of ≥ 1% weight loss yielding 63% sensitivity and 76.7% specificity. MST (score ≥ 2) resulted in 70.6% sensitivity and 69.5% specificity, AUC 0.77.
CONCLUSIONS: Both the MST and the automated method fell short of the accepted professional standard for sensitivity (~≥ 80%) derived from the PG-SGA. Further investigation into other automated nutrition screening options and the most appropriate parameters available electronically is warranted to support targeted service provision.

Entities:  

Mesh:

Year:  2014        PMID: 24647492     DOI: 10.1007/s00520-014-2210-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  5 in total

1.  Applicability of the Nutrition Risk Screening 2002 Combined with a Patient-Generated Subjective Global Assessment in Patients with Nasopharyngeal Carcinoma.

Authors:  Xiaoxian Pan; Caihong Wang; Rong Li; Li Su; Mingwei Zhang; Chuanshu Cai; Shiping Liu; Weijian Zhang; Jihong Song; Jinsheng Hong
Journal:  Cancer Manag Res       Date:  2020-09-09       Impact factor: 3.989

2.  Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF) is a valid screening tool in chemotherapy outpatients.

Authors:  Jessica Abbott; L Teleni; D McKavanagh; J Watson; A L McCarthy; E Isenring
Journal:  Support Care Cancer       Date:  2016-04-19       Impact factor: 3.603

3.  Evaluation of a weekly speech pathology/dietetic service model for providing supportive care intervention to head and neck cancer patients and their carers during (chemo)radiotherapy.

Authors:  Laurelie R Wall; Bena Cartmill; Elizabeth C Ward; Anne J Hill; Elizabeth Isenring; Sandro V Porceddu
Journal:  Support Care Cancer       Date:  2015-08-25       Impact factor: 3.603

4.  Consensus on the standard terminology used in the nutrition care of adult patients with chronic kidney disease.

Authors:  Cristina Martins; Simone L Saeki; Marcelo Mazza do Nascimento; Fernando M Lucas Júnior; Ana Maria Vavruk; Christiane L Meireles; Sandra Justino; Denise Mafra; Estela Iraci Rabito; Maria Eliana Madalozzo Schieferdecker; Letícia Fuganti Campos; Denise P J van Aanholt; Ana Adélia Hordonho; Marcia Samia Pinheiro Fidelix
Journal:  J Bras Nefrol       Date:  2021 Apr-Jun

Review 5.  Nutrition Care Process Model Approach to Surgical Prehabilitation in Oncology.

Authors:  Chelsia Gillis; Leslee Hasil; Popi Kasvis; Neil Bibby; Sarah J Davies; Carla M Prado; Malcolm A West; Clare Shaw
Journal:  Front Nutr       Date:  2021-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.